BHVN vs NRXP
BHVN: Biohaven is a clinical-stage biopharmaceutical company developing innovative therapies for immunology, neurological disorders, and metabolic diseases using proprietary protein degradation and ion channel platforms. NRXP: Clinical-stage biotech developing ketamine and NMDA receptor-modulating drugs for treatment-resistant depression, PTSD, and suicidal ideation with three candidates in late-stage FDA review.
Side-by-side fundamentals
| Metric | BHVN | NRXP | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $14.75 | $4.48 | |
| Market cap as of 2026-07-23 | $2.3B | $186M | |
| Net margin as of 2026-07-23 | n/a | -2336.5% | |
| Gross margin as of 2026-07-23 | n/a | +58.8% | |
| Operating margin as of 2026-07-23 | n/a | -1830.6% | |
| ROE as of 2026-07-23 | -450.0% | -195.8% | NRXP higher |
| ROA as of 2026-07-23 | -138.0% | -219.6% | BHVN higher |
| Debt / equity as of 2026-07-23 | 1.87 | 1.42 | NRXP lower |
| Beta as of 2026-07-23 | 2.98 | 2.14 | |
| 1-year return as of 2026-07-22 close | +12.3% | +49.8% | NRXP higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.